Oncoceutics Invited to Present ONC201 at Public Advisory Committee Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019

Al's Comment:

 This is exciting for the drug Onc-201.  The meeting is not for approval but for the FDA to learn about the drug and help guide the process to approval.  This is not done for most drugs.   


Posted on: 05/08/2019

Oncoceutics Invited to Present ONC201 at Public Advisory Committee Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019
  

 


Click HERE to return to brain tumor news headlines